Endocannabinoid system and opioid addiction: Behavioural aspects

Pharmacology Biochemistry and Behavior

Volumn 81, Issue 2 SPEC. ISS., 2005, Pages 343-359

  Fattore, Liana ^a,b   Deiana, Serena ^b   Spano, Sabrina M ^b   Cossu, Gregorio ^b   Fadda, Paola ^b   Scherma, Maria ^b   Fratta, Walter ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Addiction; Cannabinoids; Dependence; Drug abuse; Knockout mice; Opioids; Relapse; Reward; Sensitization; Tolerance; Withdrawal

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABIS; DRONABINOL; ENDOCANNABINOID; MORPHINE; NALOXONE; OPIATE; RIMONABANT;

ANALGESIA; ANIMAL BEHAVIOR; ANTICONVULSANT ACTIVITY; ATAXIA; BRAIN DEPTH STIMULATION; CANNABIS ADDICTION; CONDITIONING; CONFERENCE PAPER; DRUG DISCRIMINATION; DRUG EFFECT; DRUG SENSITIZATION; DRUG TOLERANCE; EUPHORIA; HUMAN; MOLECULAR MECHANICS; MOOD DISORDER; NEUROMODULATION; NONHUMAN; OPIATE ADDICTION; PLACE PREFERENCE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PTOSIS; RELAPSE; REWARD; TACHYCARDIA; WITHDRAWAL SYNDROME;

ANIMALIA;

EID: 19444374853     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2005.01.031     Document Type: Conference Paper

References (239)

1. M.E. Abood, and B.R. Martin Neurobiology of marijuana abuse Trends Pharmacol Sci 13 1992 201 206
2. M.E. Abood, C. Sauss, F. Fan, C.L. Tilton, and B.R. Martin Development of behavioural tolerance to delta9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain Pharmacol Biochem Behav 46 1993 575 579
3. M.D. Aceto, S.M. Scates, J.A. Lowe, and B.R. Martin Dependence on delta9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal J Pharmacol Exp Ther 278 1996 1290 1295
4. M.D. Aceto, S.M. Scates, R.K. Razdan, and B.R. Martin Anandamide, an endogenous cannabinoid, has a very low physical dependence potential J Pharmacol Exp Ther 287 1998 598 605
5. M.D. Aceto, S.M. Scates, J.A. Lowe, and B.R. Martin Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55,212-2 Eur J Pharmacol 416 2001 75 81
6. I.B. Adams, and B.R. Martin Cannabis: pharmacology and toxicology in animals and humans Addiction 91 1996 1585 1614
7. E. Ambrosio, S. Martin, C. Garcia-Lecumberri, and J.A. Crespo The neurobiology of cannabinoid dependence: sex differences and potential interactions between cannabinoid and opioid systems Life Sci 65 1999 687 694
8. A. Ameri The effects of cannabinoids on the brain Prog Neurobiol 58 1999 315 348
9. J.B. Appel, L.E. Baker, R.L. Barrett, J. Broadbent, E.M. Michael, and E.E. Riddle Use of drug discrimination in drug abuse research NIDA Res Monogr 116 1991 369 397
10. J.C. Arnold, G.E. Hunt, and I.S. McGregor Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats Life Sci 70 2001 97 108
11. I.H. Ayhan, S. Kaymakcalan, and F.C. Tulunay Interaction between delta 9-tetrahydrocannabinol and morphine on the motor activity of mice Psychopharmacology 63 1979 169 172
12. R.L. Barrett, J.L. Wiley, R.L. Balster, and B.R. Martin Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats Psychopharmacology 118 1995 419 424
13. L. Basilico, D. Parolaro, M. Colleoni, B. Costa, and G. Giagnoni Cross-tolerance and convergent dependence between morphine and cannabimimetic agent WIN 55,212-2 in the guinea-pig ileum myenteric plexus Eur J Pharmacol 376 1999 265 271
14. C.E. Bass, and B.R. Martin Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice Drug Alcohol Depend 60 2000 113 119
15. F. Berrendero, and R. Maldonado Involvement of the opioid system in the anxiolytic-like effects induced by Delta (9)-tetrahydrocannabinol Psychopharmacology 163 2002 111 117
16. 9-tetrahydrocannabinol Eur J Pharmacol 36 1976 259 262
17. H.N. Bhargava The effects of thyrotropin releasing hormone and histidyl-proline diketopiperazine on delta-9-tetrahydrocannabinol-induced hypothermia Life Sci 26 1980 845 850
18. H.N. Bhargava Multiple opiate receptors of brain and spinal cord in opiate addiction Gen Pharmacol 22 1991 767 772
19. H.N. Bhargava, and G.A. Matwyshyn Influence of thyrotropin releasing hormone and histidyl-proline diketopiperazine on spontaneous locomotor activity and analgesia induced by delta9-tetrahydrocannabinol in the mouse Eur J Pharmacol 68 1980 147 154
20. M. Bidaut-Russell, W.A. Devane, and A.C. Howlett Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain J Neurochem 55 1990 21 26
21. A.S. Bloom, and W.L. Dewey A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse Psychopharmacology 57 1978 243 248
22. A. Bonnin, R. de Miguel, J.C. Rodriguez-Manzaneque, J.J. Fernandez-Ruiz, A. Santos, and J.A. Ramos Changes in tyrosine hydroxylase gene expression in mesencephalic catecholaminergic neurons of immature and adult male rats perinatally exposed to cannabinoids Brain Res Dev Brain Res 81 1994 147 150
23. D. Braida, and M. Sala Role of the endocannabinoid system in MDMA intracerebral self-administration in rats Br J Pharmacol 136 2002 1089 1092
24. D. Braida, M. Pozzi, R. Cavallini, and M. Sala Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system Neuroscience 104 2001 923 926
25. D. Braida, M. Pozzi, D. Parolaro, and M. Sala Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system Eur J Pharmacol 413 2001 227 234
26. D. Braida, S. Iosue, S. Pegorini, and M. Sala Delta(9)- Tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats Eur J Pharmacol 506 2004 63 69
27. C.S. Breivogel, S.R. Childers, S.A. Deadwyler, R.E. Hampson, L.J. Vogt, and L.J. Sim-Selley Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain J Neurochem 73 1999 2447 2459
28. F.R. Buttarelli, F.E. Pontieri, V. Margotta, and G. Palladini Cannabinoid-induced stimulation of motor activity in planaria through an opioid receptor-mediated mechanism Prog Neuropsychopharmacol Biol Psychiatry 26 2002 65 68
29. C. Cadoni, A. Pisanu, M. Solinas, E. Acquas, and G. Di Chiara Behavioural sensitization after repeated exposure to Delta9-tetrahydrocannabinol and cross-sensitization with morphine Psychopharmacology 158 2001 259 266
30. H. Cappell, and P. Pliner Regulation of the self-administration of marijuana by psychological and pharmacological variables Psychopharmacologia 40 1974 65 76
31. J.M. Carney, I.M. Uwaydah, and R.L. Balster Evaluation of a suspension system for intravenous self-administration studies of water-insoluble compounds in the rhesus monkey Pharmacol Biochem Behav 7 1977 357 364
32. A. Castañé, P. Robledo, A. Matifas, B.L. Kieffer, and R. Maldonado Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice Eur J Neurosci 17 2003 155 159
33. 9-Tetrahydrocannabinol content and human marijuana self-administration Psychopharmacology 98 1989 51 55
34. 9-THC and smoked marijuana in humans Psychopharmacology 107 1992 255 262
35. L.D. Chait, S.M. Evans, K.A. Grant, J.B. Kamien, C.E. Johanson, and C.R. Schuster Discriminative stimulus and subjective effects of smoked marijuana in humans Psychopharmacology 94 1988 206 212
36. R.Y. Chan, and Y.H. Wong Chronic activation of ORL1 receptor induces supersensitization of adenylyl cyclase NeuroReport 10 1999 2901 2905
37. F. Chaperon, P. Soubrie, A.J. Puech, and M.H. Thiebot Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats Psychopharmacology 135 1998 324 332
38. J.P. Chen, W. Paredes, J. Li, D. Smith, J. Lowinson, and E.L. Gardner Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis Psychopharmacology 102 1990 156 162
39. R.Z. Chen, R.R. Huang, C.P. Shen, D.J. MacNeil, and T.M. Fong Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice Brain Res 999 2004 227 230
40. S.R. Childers, L. Fleming, C. Konkoy, D. Marckel, M. Pacheco, and T. Sexton Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain Ann N Y Acad Sci 654 1992 33 51
41. D.L. Cichewicz Synergistic interactions between cannabinoid and opioid analgesics Life Sci 74 2004 1317 1324
42. C. Cohen, G. Perrault, C. Voltz, R. Steinberg, and P. Soubrie SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats Behav Pharmacol 13 2002 451 463
43. R.J. Collins, J.R. Weeks, M.M. Cooper, P.I. Good, and R.R. Russell Prediction of abuse liability of drugs using IV self-administration by rats Psychopharmacology 82 1984 6 13
44. F.C. Colpaert Drug discrimination in neurobiology Pharmacol Biochem Behav 64 1999 337 345
45. D.R. Compton, W.L. Dewey, and B.R. Martin Cannabis dependence and tolerance production Adv Alcohol Subst Abuse 9 1990 129 147
46. D.R. Compton, L.S. Harris, A.H. Lichtman, and B.R. Martin Marijuana. Pharmacological aspects of drug dependence C.R. Schuster M.J. Kuhar Handbook of experimental pharmacology vol. 118 1996 Springer Verlag Berlin 83 158
47. 9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat Life Sci 61 1997 39 43
48. 9- Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus Eur J Pharmacol 323 1997 193 195
49. J. Corchero, L. Garcia-Gil, J. Manzanares, J.J. Fernandez-Ruiz, J.A. Fuentes, and J.A. Ramos Perinatal delta9-tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats Life Sci 63 1998 843 850
50. J. Corchero, J.A. Fuentes, and J. Manzanares Chronic treatment with CP-55,940 regulates corticotrophin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat Life Sci 64 1999 905 911
51. 9-THC in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen Brain Res Mol Brain Res 67 1999 148 157
52. J. Corchero, J.A. Fuentes, and J. Manzanares Gender differences in proenkephalin gene expression response to delta9-tetrahydrocannabinol in the hypothalamus of the rat J Psychopharmacol 16 2002 283 289
53. J. Corchero, J.M. Oliva, C. Garcia-Lecumberri, S. Martin, E. Ambrosio, and J. Manzanares Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain J Psychopharmacol 18 2004 54 58
54. G. Cossu, C. Ledent, L. Fattore, A. Imperato, G.A. Bohme, and M. Parmentier Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse Behav Brain Res 118 2001 61 65
55. M. Costanzi, M. Battaglia, R. Populin, V. Cestari, and C. Castellano Anandamide and memory in CD1 mice: effects of immobilization stress and of prior experience Neurobiol Learn Mem 79 2003 204 211
56. N.L. Day, G.A. Richardson, L. Goldschmidt, N. Robles, P.M. Taylor, and D.S. Stoffer Effect of prenatal marijuana exposure on the cognitive development of offspring at age three Neurotoxicol Teratol 16 1994 169 175
57. S.M. Deikel, and B. Carder Attenuation of precipitated abstinence in methadone-dependent rats by delta9-THC Psychopharmacol Commun 2 1976 61 65
58. J.M. Delfs, H. Kong, A. Mestek, Y. Chen, L. Yu, and T. Reisine Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level J Comp Neurol 345 1994 46 68
59. 9-tetrahydrocannabinol (THC) in rhesus monkeys Pharmacologist 13 1971 246 248
60. V. Deroche-Gamonet, M. Le Moal, P.V. Piazza, and P. Soubrie SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats Psychopharmacology 157 2001 254 259
61. T.J. De Vries, B.J. Van Vliet, F. Hogenboom, G. Wardeh, J.W. Van der Laan, and A.H. Mulder Effect of chronic prenatal morphine treatment of mu-opioid receptor-regulated adenylate cyclase activity and neurotransmitter release in rat brain slices Eur J Neurosci 208 1991 97 104
62. T.J. De Vries, J.R. Homberg, R. Binnekade, H. Raaso, and A.N. Schoffelmeer Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats Psychopharmacology 168 2003 164 169
63. J. De Vry, and K.R. Jentzsch Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist Eur J Pharmacol 457 2002 147 152
64. J. De Vry, and K.R. Jentzsch Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm Behav Pharmacol 14 2003 471 476
65. W.L. Dewey Cannabinoid pharmacology Pharmacol Rev 38 1986 151 178
66. W.L. Dewey, L.S. Harris, and J.S. Kennedy Some pharmacological and toxicological effects of 1-trans-8 and 1-trans-9-tetrahydrocannabinol in laboratory rodents Arch Int Pharmacodyn Ther 196 1972 133 145
67. M. Diana, M. Melis, A.L. Muntoni, and G.L. Gessa Mesolimbic dopaminergic decline after cannabinoid withdrawal Proc Natl Acad Sci 95 1998 10269 10273
68. P. Doty, L.A. Dykstra, and M.J. Picker Discriminative stimulus effects of phencyclidine: pharmacologically specific interactions with delta 9- and delta 8-tetrahydrocannabinol Drug Alcohol Depend 35 1994 151 158
69. L. Fattore, M.C. Martellotta, G. Cossu, M.S. Mascia, and W. Fratta CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats Behav Brain Res 104 1999 141 146
70. L. Fattore, M.C. Martellotta, G. Cossu, and W. Fratta Gamma-hydroxybutyric acid: an evaluation of its rewarding properties in rats and mice Alcohol 20 2000 247 256
71. L. Fattore, G. Cossu, M.S. Mascia, M.C. Obinu, C. Ledent, and M. Parmentier Role of cannabinoid CB1 receptor in morphine rewarding effects in mice Pharm Pharmacol Commmun 6 2000 1 6
72. L. Fattore, G. Cossu, C.M. Martellotta, and W. Fratta Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats Psychopharmacology 156 2001 410 416
73. L. Fattore, G. Cossu, and W. Fratta Functional interaction between cannabinoids and opioids in animal models of drug addiction Proceedings of the "Frontiers in Addiction Research" NIDA Symposium Satellite at the SfN Meeting, 1-2 Nov., Orlando (USA) 2002
74. L. Fattore, M.S. Spano, G. Cossu, S. Deiana, and W. Fratta Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats Eur J Neurosci 17 2003 1723 1726
75. L. Fattore, G. Cossu, M.S. Spano, S. Deiana, P. Fadda, and M. Scherma Cannabinoids and reward: interactions with the opioid system Crit Rev Neurobiol 16 2004 147 158
76. W. Fratta, G. Cossu, M.C. Martellotta, and L. Fattore A common neurobiological mechanism regulates cannabinoid and opioid rewarding effects in mice Neurosci Lett 52 1999 S10 S11
77. R.C. Frederickson, C.R. Hewes, and J.W. Aiken Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol J Pharmacol Exp Ther 199 1976 375 384
78. P.A. Fried Prenatal exposure to marihuana and tobacco during infancy, early and middle childhood: effects and an attempt at synthesis Arch Toxicol Suppl 17 1995 233 260
79. P.A. Fried The Ottawa prenatal prospective study (OPPS): methodological issues and findings-it's easy to throw the baby out with the bath water Life Sci 56 1995 2159 2168
80. J.A. Fuentes, M. Ruiz-Gayo, J. Manzanares, G. Vela, I. Reche, and J. Corchero Cannabinoids as potential new analgesics Life Sci 65 1999 675 685
81. E.L. Gardner, and J.H. Lowinson Marijuana's interactions with brain reward systems: update 1991 Pharmacol Biochem Behav 40 1991 571 580
82. E.L. Gardner, and S.R. Vorel Cannabinoid transmission and reward-related events Neurobiol Dis 5 1998 502 533
83. E.L. Gardner, W. Paredes, D. Smith, A. Donner, C. Milling, and D. Cohen Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol Psychopharmacology 96 1988 142 144
84. E.L. Gardner, W. Paredes, D. Smith, and R.S. Zukin Facilitation of brain stimulation reward by delta-9-tetrahydrocannabinol is mediated by an endogenous opioid mechanism Adv Biosci 75 1989 671 674
85. C. Gaveriaux-Ruff, and B.L. Kieffer Opioid receptor genes inactivated in mice: the highlights Neuropeptides 36 2002 62 71
86. S. Ghozland, H.W. Matthes, F. Simonin, D. Filliol, B.L. Kieffer, and R. Maldonado Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors J Neurosci 22 2002 1146 1154
87. L.H. Gold, R.L. Balster, R.L. Barrett, D.T. Britt, and B.R. Martin A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys J Pharmacol Exp Ther 262 1992 479 486
88. S. Gonzalez, P.C. Schmid, J. Fernandez-Ruiz, R. Krebsbach, H.H. Schmid, and J.A. Ramos Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats Addict Biol 8 2003 159 166
89. S. Gonzalez, J. Fernandez-Ruiz, V.D. Marzo, M. Hernandez, C. Arevalo, and C. Nicanor Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence Drug Alcohol Depend 74 2004 159 170
90. M.A. Gorriti, F. Rodriguez de Fonseca, M. Navarro, and T. Palomo Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats Eur J Pharmacol 365 1999 133 142
91. M. Haney, A. Bisaga, and R.W. Foltin Interaction between naltrexone and oral THC in heavy marijuana smokers Psychopharmacology 166 2003 77 85
92. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J Neurosci 11 1991 563 583
93. B. Hine Morphine and delta 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat Psychopharmacology 87 1985 34 38
94. B. Hine, M. Torrelio, and S. Gershon Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC Psychopharmacol Commun 1 1975 275 283
95. B. Hine, M. Torrelio, and S. Gershon Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats Life Sci 17 1975 851 857
96. I.D. Hirschhorn, and J.A. Rosecrans Morphine and delta 9-tetrahydrocannabinol: tolerance to the stimulus effects Psychopharmacologia 36 1974 243 253
97. S.G. Holtzman Drug discrimination studies Drug Alcohol Depend 14 1985 263 282
98. 9-THC and anandamide Brain Res 857 2000 337 342
99. A.C. Howlett Pharmacology of cannabinoid receptors Annu Rev Pharmacol Toxicol 35 1995 607 634
100. D.M. Hutcheson, E.T. Tzavara, C. Smadja, E. Valjent, B.P. Roques, and J. Hanoune Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol Br J Pharmacol 125 1998 1567 1577
101. D.E. Hutchings, B.R. Martin, Z. Gamagaris, N. Miller, and T. Fico Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats Life Sci 44 1989 697 701
102. 9-tetrahydrocannabinol in man Psychopharmacologia 11 1967 184 188
103. A.A. Izzo, N. Mascolo, L. Pinto, R. Capasso, and F. Capasso The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats Eur J Pharmacol 384 1999 37 42
104. A.A. Izzo, N. Mascolo, M. Tonini, and F. Capasso Modulation of peristalsis by cannabinoid CB(1) ligands in the isolated guinea-pig ileum Br J Pharmacol 129 2000 984 990
105. A. Jakubovic, T. Hattori, and P.L. Mc Geer Radioactivity in suckled rats after giving 14C-tetrahydrocannabinol to the mother Eur J Pharmacol 22 1977 221 223
106. T.U.C. Järbe, and A.J. Hiltunen Limited stimulus generalization between delta9-THC and diazepam in pigeons and gerbils Psychopharmacology 94 1988 328 331
107. 9-THC and its interaction with naltrexone and catecholamine blockers in rats Psychopharmacology 54 1977 193 195
108. 9-THC training dose as a determinant for (R)-methanandamide generalization in rats Psychopharmacology 140 1998 519 522
109. T.U.C. Järbe, M.E. Andrzejewski, and N.V. DiPatrizio Interactions between the CB1 receptor agonist delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited Pharmacol Biochem Behav 73 2002 911 919
110. Z. Justinova, G. Tanda, G.H. Redhi, and S.R. Goldberg Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys Psychopharmacology 169 2003 135 140
111. Z. Justinova, G. Tanda, P. Munzar, and S.R. Goldberg The opioid antagonist naltrexone reduces the reinforcing effects of Delta9- tetrahydrocannabinol (THC) in squirrel monkeys Psychopharmacology 173 2004 186 194
112. S. Kaymakcalan, I.H. Ayhan, and F.C. Tulunay Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats Psychopharmacology 55 1977 243 249
113. T.C. Kirkham, and C.M. Williams Synergistic effects of opioid and cannabinoid antagonists on food intake Psychopharmacology 153 2001 267 270
114. G.F. Koob Neural mechanisms of drug reinforcement Ann N Y Acad Sci 654 1992 171 191
115. G.F. Koob Drugs of abuse: anatomy, pharmacology and function of reward pathways Trends Pharmacol Sci 13 1992 177 184
116. G.F. Koob Drug addiction: the yin and yang of hedonic homeostasis Neuron 16 1996 893 896
117. R.K. Kubena, J.L. Perhach Jr., and H. Barry III Corticosterone elevation mediated centrally by delta 1-tetrahydrocannabinol in rats Eur J Pharmacol 14 1971 89 92
118. A. Kulkarni-Narla, and D.R. Brown Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons Neurosci Lett 308 2001 153 156
119. A.M. Kumar, M. Haney, T. Becker, M.L. Thompson, R.M. Kream, and K. Miczek Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain Brain Res 525 1990 78 83
120. A. Kuzmin, E. Zvartau, G.L. Gessa, M.C. Martellotta, and W. Fratta Calcium antagonists isradipine and nimodipine suppress cocaine and morphine intravenous self-administration in drug-naive mice Pharmacol Biochem Behav 41 1992 497 500
121. S. Lamarque, K. Taghzouti, and H. Simon Chronic treatment with Delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin. Implications for vulnerability to drug addiction Neuropharmacology 41 2001 118 129
122. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J.F. Aubert, and F. Beslot Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice Science 283 1999 401 404
123. L. Lemberger, N.R. Tamarkin, J. Axelrod, and I.J. Kopin Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marijuana smokers Science 173 1971 72 74
124. M. Lepore, S.R. Vorel, J. Lowinson, and E.L. Gardner Conditioned place preference induced by delta 9-tetrahydrocannabinol: comparison with cocaine, morphine, and food reward Life Sci 56 1995 2073 2080
125. M. Lepore, X. Liu, V. Savage, D. Matalon, and E.L. Gardner Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains Life Sci 58 1996 PL365 PL372
126. A.H. Lichtman, and B.R. Martin Marijuana withdrawal syndrome in the animal model J Clin Pharmacol 42 2002 20S 27S
127. A.H. Lichtman, S.M. Sheikh, H.H. Loh, and B.R. Martin Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)- tetrahydrocannabinol and morphine-dependent mice J Pharmacol Exp Ther 298 2001 1007 1014
128. R. Maldonado, L. Stinus, L.H. Gold, and G.F. Koob Role of different brain structures in the expression of the physical morphine withdrawal syndrome J Pharmacol Exp Ther 261 1992 669 677
129. R.S. Mansbach, K.L. Nicholson, B.R. Martin, and R.L. Balster Failure of delta(9)-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys Behav Pharmacol 5 1994 219 225
130. 9-tetrahydrocannabinol in rats Brain Res 839 1999 173 179
131. J. Mao, D.D. Price, J. Lu, L. Keniston, and D.J. Mayer Two distinctive antinociceptive systems in rats with pathological pain Neurosci Lett 280 2000 13 16
132. S. Marín, E. Marco, M. Biscaia, B. Fernàndez, M. Rubio, and C. Guaza Involvement of the oc-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats Pharmacol Biochem Behav 74 2003 649 656
133. M.C. Martellotta, A. Kuzmin, E. Zvartau, G. Cossu, G.L. Gessa, and W. Fratta Isradipine inhibits nicotine intravenous self-administration in drug-naive mice Pharmacol Biochem Behav 52 1995 271 274
134. M.C. Martellotta, G. Cossu, L. Fattore, G.L. Gessa, and W. Fratta Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice Neuroscience 85 1998 327 330
135. B.R. Martin Characterization of the antinociceptive activity of intravenously administered delta-9-tetrahydrocannabinol in mice D.J. Harvey Marijuana '84, Proceeding of the Oxford Symposium on Cannabis 1985 IRL Oxford (UK) 685 692
136. B.R. Martin, W.L. Dewey, L.S. Harris, and J.S. Beckner 3H-delta9-tetrahydrocannabinol tissue and subcellular distribution in the central nervous system and tissue distribution in peripheral organs of tolerant and nontolerant dogs J Pharmacol Exp Ther 196 1976 128 144
137. S. Martin, J.A. Crespo, R. Ferrado, C. Garcia-Lecumberri, L. Gil, and J.A. Ramos Effects of delta-9-THC perinatal treatment of mothers on morphine and food operant reinforced behaviours in the adult offspring Abstr-Soc Neurosci 22 1996 167
138. M. Martin, C. Ledent, M. Parmentier, R. Maldonado, and O. Valverde Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice Eur J Neurosci 12 2000 4038 4046
139. B.R. Martin, L.J. Sim-Selley, and D.E. Selley Signaling pathways involved in the development of cannabinoid tolerance Trends Pharmacol Sci 25 2004 325 330
140. M. Mas-Nieto, B. Pommier, E.T. Tzavara, A. Caneparo, S. Da Nascimento, and G. Le Fur Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction Br J Pharmacol 132 2001 1809 1816
141. P. Massi, A. Vaccani, S. Romorini, and D. Parolaro Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects J Neuroimmunol 117 2001 116 124
142. P. Massi, A. Vaccani, T. Rubino, and D. Parolaro Cannabinoids and opioids share cAMP pathway in rat splenocytes J Neuroimmunol 145 2003 46 54
143. L.A. Matsuda, T.I. Bonner, and S.J. Lolait Localization of cannabinoid receptor mRNA in rat brain J Comp Neurol 327 1993 535 550
144. R. Mechoulam, and L. Parker Cannabis and alcohol-a dose friendship Trends Pharmacol Sci 24 2003 266 268
145. L.S. Melvin, G.M. Milne, M.R. Johnson, B. Subramaniam, G.H. Wilken, and A.C. Howlett Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs Mol Pharmacol 44 1993 1008 1015
146. J.H. Mendelson, N.K. Mello, B.W. Lex, and S. Bavli Marijuana withdrawal syndrome in a woman Am J Psychiatry 141 1984 1289 1290
147. M. Mirmiran, and D.F. Swaab Influence of drugs on brain neurotransmitters and behavioral states during development Dev Pharmacol Ther 10 1987 377 384
148. D.J. Mokler, B.D. Nelson, L.S. Harris, and J.A. Rosecrans The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol Life Sci 38 1986 1581 1589
149. S. Narimatsu, I. Yamamoto, K. Watanabe, and H. Yoshimura Change in hypothermia and catalepsy induced by cannabinoids or morphine in mice tolerant to these substances Eur J Pharmacol 141 1987 437 443
150. M. Navarro, R. de Miguel, F. Rodriguez de Fonseca, J.A. Ramos, and J.J. Fernandez-Ruiz Perinatal cannabinoid exposure modifies the sociosexual approach behavior and the mesolimbic dopaminergic activity of adult male rats Behav Brain Res 75 1996 91 98
151. M. Navarro, J. Chowen, M. Rocio A Carrera, I. del Arco, M.A. Villanua, and Y. Martin CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats NeuroReport 9 1998 3397 3402
152. M. Navarro, M.R. Carrera, W. Fratta, O. Valverde, G. Cossu, and L. Fattore Functional interaction between opioid and cannabinoid receptors in drug self-administration J Neurosci 21 2001 5344 5350
153. E.J. Nestler Molecular mechanisms of drug addiction J Neurosci 12 1992 2439 2450
154. E.J. Nestler, J.J. Erdos, R. Terwilliger, R.S. Duman, and J.F. Tallman Regulation of G proteins by chronic morphine in the rat locus coeruleus Brain Res 476 1989 230 239
155. C.S. Norwood, J.L. Cornish, P.E. Mallet, and I.S. McGregor Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioural sensitization and alters morphine self-administration in Lewis rats Eur J Pharmacol 465 2003 105 114
156. J. Olds, and P. Milner Positive reinforcement produced by electrical stimulation of septal area and other regions of the rat brain J Comp Physiol 1954 419 427
157. A. Oviedo, J. Glowa, and M. Herkenham Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study Brain Res 616 1993 293 302
158. A. Perez-Rosado, J. Manzanares, J. Fernandez-Ruiz, and J.A. Ramos Prenatal Delta(9)-tetrahydrocannabinol exposure modifies proenkephalin gene expression in the fetal rat brain: sex-dependent differences Brain Res Dev Brain Res 120 2000 77 81
159. R.G. Pertwee The central neuropharmacology of psychotropic cannabinoids Pharmacol Ther 36 1988 189 261
160. R.G. Pertwee, and G. Griffin A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens Eur J Pharmacol 272 1995 67 72
161. R. Pickens Self-administration of stimulants by rats Int J Addict 3 1968 215 221
162. R. Pickens, T. Thompson, and D.C. Muchow Cannabis and phencyclidine self-administered by animals L. Goldfarb F. Hoffmeister Psychic dependence (Bayer-Symposium IV) 1973 Springer-Verlag Berlin 78 86
163. T.A. Pietras, and N.E. Rowland Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats Eur J Pharmacol 442 2002 237 239
164. M. Poncelet, M.C. Barnouin, J.C. Breliere, G. Le Fur, and P. Soubrie Blockade of cannabinoid (CB1) receptors by SR141716A selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils Psychopharmacology 114 1999 144 150
165. F.E. Pontieri, P. Monnazzi, A. Scontrini, F.R. Buttarelli, and F.R. Patacchioli Behavioral sensitization to heroin by cannabinoid pretreatment in the rat Eur J Pharmacol 421 2001 R1 R3
166. F.E. Pontieri, P. Monnazzi, A. Scontrini, F.R. Buttarelli, and F.R. Patacchioli Behavioral sensitization to WIN55212.2 in rats pretreated with heroin Brain Res 898 2001 178 180
167. S.N. Pradhan, A.K. Bhattacharyya, C.S. Aulakh, S. Pradhan, and P.T. Bailey Cannabis and brain-stimulation reward Adv Biosci 22 1978 567 583
168. K.L. Preston Drug discrimination methods in human drug abuse liability evaluation Br J Addict 86 1991 1587 1594
169. 9-tetrahydrocannabinol and morphine in the spinal cord J Pharmacol Exp Ther 279 1996 608 616
170. G. Pugh Jr., D.J. Mason, V. Combs, and S.P. Welch Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the
171. T. Reisine, and M.J. Brownstein Opioid and cannabinoid receptors Curr Opin Neurobiol 4 1994 406 412
172. M.H. Rhee, I. Nevo, T. Avidor-Reiss, R. Levy, and Z. Vogel Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor Mol Pharmacol 57 2000 746 752
173. O.V. Rice, N. Gordon, and A.N. Gifford Conditioned place preference to morphine in cannabinoid CB1 receptor knockout mice Brain Res 945 2002 135 138
174. M. Rinaldi-Carmona, F. Pialot, C. Congy, E. Redon, F. Barth, and A. Bachy Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain Life Sci 58 1996 1239 1247
175. F. Rodriguez de Fonseca, M. Cebeira, J.J. Fernandez-Ruiz, M. Navarro, and J.A. Ramos Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons Neuroscience 43 1991 713 723
176. F. Rodriguez de Fonseca, J.A. Ramos, A. Bonnin, and J.J. Fernandez-Ruiz Presence of cannabinoid binding sites in the brain from early postnatal ages NeuroReport 4 1993 135 138
177. F. Rodriguez de Fonseca, M.A. Gorriti, J.J. Fernandez-Ruiz, T. Palomo, and J.A. Ramos Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment Pharmacol Biochem Behav 47 1994 33 40
178. F. Rodriguez de Fonseca, M.A. Villanua, R.M. Munoz, O. San-Martin-Clark, and M. Navarro Differential effects of chronic treatment with either dopamine D1 or D2 receptor agonists on the acute neuroendocrine actions of the highly potent synthetic cannabinoid HU-210 in male rats Neuroendocrinology 61 1995 714 721
179. F. Rodriguez de Fonseca, M.R. Carrera, M. Navarro, G.F. Koob, and F. Weiss Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal Science 276 1997 2050 2054
180. J. Romero, L. Garcia, J.J. Fernandez-Ruiz, M. Cebeira, and J.A. Ramos Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol Pharmacol Biochem Behav 51 1995 731 737
181. J. Romero, F. Berrendero, L. Garcia-Gil, J.A. Ramos, and J.J. Fernandez-Ruiz Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9- tetrahydrocannabinol J Mol Neurosci 11 1998 109 119
182. J. Romero, F. Berrendero, J. Manzanares, A. Perez, J. Corchero, and J.A. Fuentes Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol Synapse 30 1998 298 308
183. J. Romero, J.-J. Fernandez-Ruiz, G. Vela, M. Ruiz-Gayo, J.A. Fuentes, and J.A. Ramos Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTPDS binding in morphine-dependent mice Drug Alcohol Depend 50 1998 241 249
184. D.W. Rowen, J.P. Embrey, C.H. Moore, and S.P. Welch Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance Pharmacol Biochem Behav 59 1998 399 404
185. N.E. Rowland, M. Mukherjee, and K. Robertson Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats Psychopharmacology 159 2001 111 116
186. T. Rubino, G. Patrini, M. Parenti, P. Massi, and D. Parolaro Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system Mol Brain Res 44 1997 191 197
187. T. Rubino, L. Tizzoni, D. Viganò, P. Massi, and D. Parolaro Modulation of rat brain cannabinoid receptors after chronic morphine treatment NeuroReport 8 1997 3219 3223
188. T. Rubino, P. Massi, D. Vigano, D. Fuzio, and D. Parolaro Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome Life Sci 66 2000 2213 2219
189. T. Rubino, D. Viganò, P. Massi, and D. Parolaro The psychoactive ingredient of marijuana induces behavioural sensitization Eur J Neurosci 14 2001 884 886
190. 9-tetrahydrocannabinol behavioural sensitization Eur J Neurosci 17 2003 325 330
191. 9-tetrahydrocannabinol in rats: possible role of pituitary-adrenal axis Life Sci 56 1995 2169 2176
192. P. Rubio, F.R. de Fonseca, J.L. Martin-Calderon, I. Del Arco, S. Bartolome, and M.A. Villanua Maternal exposure to low doses of delta9-tetrahydrocannabinol facilitates morphine-induced place conditioning in adult male offspring Pharmacol Biochem Behav 61 1998 229 238
193. M.C. Sanudo-Pena, K. Tsou, E.R. Delay, A.G. Hohman, M. Force, and J.M. Walker Endogenous cannabinoids as an aversive or counter-rewarding system in the rat Neurosci Lett 223 1997 125 128
194. M.C. Sanudo-Pena, J. Romero, G.E. Seale, J.J. Fernandez-Ruiz, and J.M. Walker Activational role of cannabinoids on movement Eur J Pharmacol 391 2000 269 274
195. D.W. Self, and L. Stein Receptor subtypes in opioid and stimulant reward Pharmacol Toxicol 70 1992 87 94
196. M. Shapira, Z. Vogel, and Y. Sarne Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors Cell Mol Neurobiol 20 2000 291 304
197. A.J. Siemens, and H. Kalant Metabolism of delta 1-tetrahydrocannabinol by rats tolerant to cannabis Can J Physiol Pharmacol 52 1974 1154 1166
198. L.J. Sim, D.E. Selley, R. Xiao, and S.R. Childers Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum Eur J Pharmacol 307 1996 97 105
199. L.J. Sim, R.E. Hampson, S.A. Deadwyler, and S.R. Childers Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain J Neurosci 16 1996 8057 8066
200. I.I. Simoneau, M.S. Hamza, H.P. Mata, E.M. Siegel, T.W. Vanderah, and F. Porreca The cannabinoid agonist WIN 55,212-2 suppresses opioid-induced emesis in ferrets Anesthesiology 94 2001 882 887
201. L.J. Sim-Selley Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids Crit Rev Neurobiol 15 2003 91 119
202. M.E. Singh, A.N. Verty, I.S. McGregor, and P.E. Mallet A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine Brain Res 1026 2 2004 244 253
203. N.T. Smith A review of the published literature into cannabis withdrawal symptoms in human users Addiction 97 2002 621 632
204. Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology [in press].
205. M. Solinas, L.V. Panlilio, K. Antoniou, L.A. Pappas, and S.R. Goldberg The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats J Pharmacol Exp Ther 306 2003 93 102
206. S. Spano, L. Fattore, G. Cossu, S. Deiana, P. Fadda, and W. Fratta CB1 receptor agonists and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat Br J Pharmacol 143 2004 343 350
207. I.P. Stolerman Components of drug dependence: reinforcement, discrimination and adaptation Biochem Soc Symp 59 1993 1 12
208. R.N. Takahashi, and G. Singer Self-administration of delta 9-tetrahydrocannabinol by rats Pharmacol Biochem Behav 11 1979 737 740
209. G. Tanda, and S.R. Goldberg Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data Psychopharmacology 169 2003 115 134
210. G. Tanda, P. Munzar, and S.R. Goldberg Self-administration behaviour is maintained by the psychoactive ingredient of marijuana in squirrel monkeys Nat Neurosci 3 2000 1073 1074
211. S.N. Thorat, and H.N. Bhargava Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice Eur J Pharmacol 260 1994 5 13
212. 9- tetrahydrocannabinol on hypothalamically induced feeding Psychopharmacology 103 1991 172 176
213. K. Tsou, S.L. Patrick, and J.M. Walker Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist Eur J Pharmacol 280 1995 R13 R15
214. 9-tetrahydrocannabinol in rats Eur J Pharmacol 70 1981 219 224
215. F.C. Tulunay, I.H. Ayhan, and S.B. Sparber The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats Psychopharmacology 78 1982 358 360
216. E.T. Tzavara, E. Valjent, C. Firmo, M. Mas, F. Beslot, and N. Defer Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum Eur J Neurosci 12 2000 1038 1046
217. T.M. Tzschentke Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues Prog Neurobiol 56 1998 613 672
218. E. Ulku, I.H. Ayhan, F.C. Tulunay, B. Uran, and S. Kaymakcalan Effect of delta 9-tetrahydrocannabinol on the morphine-induced hyperactivity of mice Psychopharmacology 69 1980 201 205
219. O. Valverde, C. Ledent, F. Beslot, M. Parmentier, and B.P. Roques Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors Eur J Neurosci 12 2000 533 539
220. O. Valverde, R. Maldonado, E. Valjent, A.M. Zimmer, and A. Zimmer Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice J Neurosci 20 2000 9284 9289
221. 9-Tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect Eur J Neurosci 13 2001 1816 1824
222. J.M. van Ree, J.L. Slangen, and D. de Wied Intravenous self-administration of drugs in rats J Pharmacol Exp Ther 204 1978 547 557
223. C. Vasquez, and D.L. Lewis The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors J Neurosci 19 1999 9271 9280
224. G. Vela, M. Ruiz-Gayo, and J.A. Fuentes Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine Neuropharmacology 34 1995 665 668
225. 9-tetrahydrocannabinol leads to changes in opioid-related behavioural patterns in rats Brain Res 680 1995 142 147
226. G. Vela, S. Martin, L. Garcia-Gil, J.A. Crespo, M. Ruiz-Gayo, and J. Javier Fernandez-Ruiz Maternal exposure to delta9-tetrahydrocannabinol facilitates morphine self-administration behavior and changes regional binding to central mu opioid receptors in adult offspring female rats Brain Res 807 1998 101 109
227. 9-THC in humans Drug Alcohol Depend 59 2000 251 260
228. D.E. Walters, and L.A. Carr Changes in brain catecholamine mechanisms following perinatal exposure to marijuana Pharmacol Biochem Behav 25 1986 763 768
229. D.E. Walters, and L.A. Carr Perinatal exposure to cannabinoids alters neurochemical development in rat brain Pharmacol Biochem Behav 29 1988 213 216
230. S.P. Welch Blockade of cannabinoid-induced antinociception by nor-binaltorphimine, but not N,N-diallyl-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice J Pharmacol Exp Ther 256 1993 633 640
231. S.P. Welch, and M. Eads Synergistic interactions of endogenous opioids and cannabinoid systems Brain Res 848 1999 183 190
232. G.A. Wiesbeck, M.A. Schuckit, J.A. Kalmijn, J.E. Tipp, K.K. Bucholz, and T.L. Smith An evaluation of the history of a marijuana withdrawal syndrome in a large population Addiction 91 1996 1469 1478
233. J.L. Wiley, and B.R. Martin Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination Pharmacol Biochem Behav 64 1999 519 522
234. R.A. Wise, and M.A. Bozarth Brain substrates for reinforcement and drug self-administration Prog Neuropsychopharmacol 5 1981 467 474
235. R.A. Wise, and D.C. Hoffman Localization of drug reward mechanisms by intracranial injections Synapse 10 1992 247 263
236. T. Yamamoto, and K. Takada Role of cannabinoid receptor in the brain as relates to drug reward Jpn J Pharmacol 84 2000 229 236
237. R.A. Yokel Intravenous self-administration: response rate, the effects of pharmacological challenges, and drug preference M.A. Bozarth Methods of assessing the reinforcing properties of abused drugs 1986 Springer Berlin 1 33
238. A.M. Young, S. Herling, and J.H. Woods History of drug exposure as a determinant of drug self administration NIDA Res Monogr 37 1981 75 88
239. A. Zimmer, E. Valjent, M. Konig, A.M. Zimmer, P. Robledo, and H. Hahn Absence of delta-9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice J Neurosci 21 2001 9499 9505